S&P 500   3,163.62 (+0.27%)
DOW   26,342.11 (+0.98%)
AAPL   381.51 (-0.10%)
MSFT   206.55 (-0.25%)
FB   236.44 (-1.07%)
GOOGL   1,497.60 (-0.97%)
NVDA   404.98 (+0.72%)
MU   49.14 (-0.67%)
TSLA   1,504.44 (+0.49%)
AMD   54.02 (+0.80%)
T   29.87 (+0.34%)
DIS   117.93 (+1.45%)
NFLX   515.22 (-1.96%)
BAC   23.82 (-1.57%)
BA   176.64 (+0.56%)
S&P 500   3,163.62 (+0.27%)
DOW   26,342.11 (+0.98%)
AAPL   381.51 (-0.10%)
MSFT   206.55 (-0.25%)
FB   236.44 (-1.07%)
GOOGL   1,497.60 (-0.97%)
NVDA   404.98 (+0.72%)
MU   49.14 (-0.67%)
TSLA   1,504.44 (+0.49%)
AMD   54.02 (+0.80%)
T   29.87 (+0.34%)
DIS   117.93 (+1.45%)
NFLX   515.22 (-1.96%)
BAC   23.82 (-1.57%)
BA   176.64 (+0.56%)
S&P 500   3,163.62 (+0.27%)
DOW   26,342.11 (+0.98%)
AAPL   381.51 (-0.10%)
MSFT   206.55 (-0.25%)
FB   236.44 (-1.07%)
GOOGL   1,497.60 (-0.97%)
NVDA   404.98 (+0.72%)
MU   49.14 (-0.67%)
TSLA   1,504.44 (+0.49%)
AMD   54.02 (+0.80%)
T   29.87 (+0.34%)
DIS   117.93 (+1.45%)
NFLX   515.22 (-1.96%)
BAC   23.82 (-1.57%)
BA   176.64 (+0.56%)
S&P 500   3,163.62 (+0.27%)
DOW   26,342.11 (+0.98%)
AAPL   381.51 (-0.10%)
MSFT   206.55 (-0.25%)
FB   236.44 (-1.07%)
GOOGL   1,497.60 (-0.97%)
NVDA   404.98 (+0.72%)
MU   49.14 (-0.67%)
TSLA   1,504.44 (+0.49%)
AMD   54.02 (+0.80%)
T   29.87 (+0.34%)
DIS   117.93 (+1.45%)
NFLX   515.22 (-1.96%)
BAC   23.82 (-1.57%)
BA   176.64 (+0.56%)
Log in

NASDAQ:SESNSesen Bio Stock Price, Forecast & News

$0.67
-0.01 (-1.03 %)
(As of 07/14/2020 01:26 PM ET)
Add
Compare
Today's Range
$0.67
Now: $0.67
$0.70
50-Day Range
$0.70
MA: $0.75
$0.82
52-Week Range
$0.37
Now: $0.67
$1.54
Volume10,485 shs
Average Volume532,002 shs
Market Capitalization$74.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.1
Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Read More
Sesen Bio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SESN
CUSIPN/A
CIKN/A
Phone617-444-8550

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$430,000.00
Book Value($0.26) per share

Profitability

Net Income$-107,500,000.00

Miscellaneous

Employees24
Market Cap$74.31 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive SESN News and Ratings via Email

Sign-up to receive the latest news and ratings for SESN and its competitors with MarketBeat's FREE daily newsletter.

Sesen Bio (NASDAQ:SESN) Frequently Asked Questions

How has Sesen Bio's stock been impacted by COVID-19 (Coronavirus)?

Sesen Bio's stock was trading at $0.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SESN stock has decreased by 6.5% and is now trading at $0.6730. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sesen Bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sesen Bio in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sesen Bio.

When is Sesen Bio's next earnings date?

Sesen Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Sesen Bio.

How were Sesen Bio's earnings last quarter?

Sesen Bio Inc (NASDAQ:SESN) released its quarterly earnings data on Monday, May, 11th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.40. View Sesen Bio's earnings history.

What price target have analysts set for SESN?

3 equities research analysts have issued 1 year target prices for Sesen Bio's shares. Their forecasts range from $2.25 to $5.00. On average, they expect Sesen Bio's share price to reach $3.63 in the next year. This suggests a possible upside of 438.6% from the stock's current price. View analysts' price targets for Sesen Bio.

Has Sesen Bio been receiving favorable news coverage?

Headlines about SESN stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sesen Bio earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Sesen Bio.

Who are some of Sesen Bio's key competitors?

What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include XOMA (XOMA), Amarin (AMRN), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Verastem (VSTM), Micron Technology (MU), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Clovis Oncology (CLVS) and AVEO Pharmaceuticals (AVEO).

Who are Sesen Bio's key executives?

Sesen Bio's management team includes the following people:
  • Mr. Richard F. Fitzgerald, CFO, Sec. & Treasurer (Age 55)
  • Dr. Thomas R. Cannell, Pres, CEO & Director (Age 57)
  • Dr. K. Christopher Garcia, Co-Founder & Member of Scientific Advisory Board
  • Dr. Gregory L. Verdine, Co-Founder (Age 60)
  • Dr. Casey T. Weaver, Co-Founder & Member of Scientific Advisory Board

What is Sesen Bio's stock symbol?

Sesen Bio trades on the NASDAQ under the ticker symbol "SESN."

How do I buy shares of Sesen Bio?

Shares of SESN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sesen Bio's stock price today?

One share of SESN stock can currently be purchased for approximately $0.67.

How big of a company is Sesen Bio?

Sesen Bio has a market capitalization of $74.31 million and generates $430,000.00 in revenue each year. The company earns $-107,500,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Sesen Bio employs 24 workers across the globe.

What is Sesen Bio's official website?

The official website for Sesen Bio is www.sesenbio.com.

How can I contact Sesen Bio?

Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-444-8550 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.